Active clinical trials of the Pediatric Early Clinical Trials East Network.
Please find here an overview of our current clincical trial portfolio.
If you are interested in participating in a specific study,
Active clinical trials of the Research Network
On this page you will find an overview of our currently active studies. If you are interested in participating in a specific study, please email the contact person at the respective clinics. You will find the contact information via the respective link to the website of the respective study locations.
Leukemias
Investigational drug: Bosutinib
Indication: newly diagnosed chronic phase or resistant/intolerant Ph+ CML
Phase: I/II
Protocol Nr.: ITCC-054/COG AAML1921
EudraCT/NCT-Nr.: EudraCT2015-002916-34
Trial location: Berlin, Charité
Investigational drug: Cellgene JCAR
Indication: B-ALL + B-NHL
Phase: I/II
Protocol Nr.: JCAR017-BCM-004
EudraCT/NCT-Nr.: EudraCT2018-001246-34
Trial location: Berlin, Charité
Investigational drug: Daratumomab
Indication: ALL
Phase: II
Protocol Nr.: 54767414ALL2005
EudraCT/NCT-Nr.: EudraCT2017-003377-34
Trial location: Berlin, Charité
Investigational drug: Inotuzumab/CD22
Indication: CD22+ relapsed/refractory BCP-ALL
Phase: II
Protocol Nr.: ITTC-059 / NTR5736
EudraCT/NCT-Nr.: EudraCT2016-000227-71
Trial location: Berlin, Charité
Investigational drug: MB-CART19.1
Indication: B-ALL REZ
Phase: II/III
Protocol Nr.: M-2017-322
EudraCT/NCT-Nr.: EudraCT2017‐002848‐32
Trial location: Berlin, Charité
Investigational drug: Midostaurin
Indication: FLT3pos AML
Phase: II
Protocol Nr.: CPKC412A2218
EudraCT/NCT-Nr.: EudraCT2017-004830-28
Trial location: Berlin, Charité
Lymphomas
Investigational drug: Bosutinib
Indication: newly diagnosed chronic phase or resistant/intolerant Ph+ CML
Phase: I/II
Protocol Nr.: ITCC-054/COG AAML1921
EudraCT/NCT-Nr.: EudraCT2015-002916-34
Trial location: Berlin, Charité
Investigational drug: Brigatinib
Indication: ALK+ ALCL, Solid Tumors, IMT
Phase: I/II
Protocol Nr.: ITCC-098 Briga Ped
EudraCT/NCT-Nr.: EudraCT2021-002713-34
Trial location: Berlin, Charité
Investigational drug: Cellgene JCAR
Indication: B-ALL + B-NHL
Phase: I/II
Protocol Nr.: JCAR017-BCM-004
EudraCT/NCT-Nr.: EudraCT2018-001246-34
Trial location: Berlin, Charité
Investigational drug: Pembrolizumab
Indication: Hodgkin Lymphoma
Phase: II
Protocol Nr.: Keynote 667
EudraCT/NCT-Nr.: EudraCT2017-001123-53
Trial location: Berlin, Charité
Solid Tumors
Investigational drug: Abemaciclib
Indication: Relapsed/Refractory Solid Tumors
Phase: I/II
Protocol Nr.: JP04
EudraCT/NCT-Nr.: NCT05440786
Trial location: Berlin, Charité
Investigational drug: Abemaciclib LY2835219
Indication: Relapsed/Refractory Solid Tumors
Phase: Ib
Protocol Nr.: I3Y-MC-JPCS
EudraCT/NCT-Nr.: EudraCT2019-002931-27
Trial location: Berlin, Charité
Investigational drug: Brigatinib
Indication: ALK+ ALCL, Solid Tumors, IMT
Phase: I/II
Protocol Nr.: ITCC-098 Briga Ped
EudraCT/NCT-Nr.: EudraCT2021-002713-34
Trial location: Berlin, Charité
Investigational drug: Dinutuximab beta
Indication: Neuroblastoma, relapsed/refraktory
Phase: I/II
Protocol Nr.: APN311-304
EudraCT/NCT-Nr.: EudraCT2014-000588-42
Trial location: Berlin, Charité
Investigational drug: Larotrectinib
Indication: Solid Tumors
Phase: I/II
Protocol Nr.: SCOUT Bayer (LOXO-TRK-15003G)
EudraCT/NCT-Nr.: EudraCT2016-003498-16
Trial location: Berlin, Charité
Investigational drug: Nivolumab + Entinostat
Indication: Refractory high risk malignoma
Phase: I/II
Protocol Nr.: INFORM2 NivEnt
EudraCT/NCT-Nr.: EudraCT2018-000127-14
Trial location: Berlin, Charité
Investigational drug: Venetoclax
Indication: NHL, Neuroblastoma
Phase: I
Protocol Nr.: M13-838
EudraCT/NCT-Nr.: EudraCT2017-000439-14
Trial location: Berlin, Charité
ZNS Tumors
Investigational drugs: DAY101 FIREFLY-1
Indication: pan RAFi
Phase: I/II
Protocol Nr.: FireFly DAY 101
EudraCT/NCT-Nr.: EudraCT2020-003657-30
Trial location: Berlin, Charité
Investigational drug: Larotrectinib
Indication: Solid Tumors
Phase: I/II
Protocol Nr.: SCOUT Bayer (LOXO-TRK-15003G)
EudraCT/NCT-Nr.: EudraCT2016-003498-16
Trial location: Berlin, Charité
Investigational drug: Selumetinib
Indication: NF1 Related Symptomatic, Inoperable Plexiform Neurofibromas (PN)
Phase: I/II
Protocol Nr.: SPRINKLE D1346C00004
EudraCT/NCT-Nr.: EudraCT2020-005608-20
Trial location: Berlin, Charité
Other deseases
Investigational drug: CDZ173/Leniolisib
Indication: NF1 Related Symptomatic, Inoperable Plexiform Neurofibromas (PN)
Phase: II/III
Protocol Nr.: CCDZ173X2201
EudraCT/NCT-Nr.: EudraCT2016-000468-41
Trial location: Dresden
Investigational drug: Crizanlizumab
Indication: Sickel cell disease
Phase: II
Protocol Nr.: CSEG 101B2201
EudraCT/NCT-Nr.: EudraCT2017-001747-12
Trial location: Berlin, Charité